TG Therapeutics Q1 BRIUMVI revenue $50.5M, raises FY guidance to $270-290M

TG THERAPEUTICS, INC.

2025-Q1 EPS reported -$0.07 revenue$63,474,000

BRIUMVI U.S. net revenue $50.5M in Q1 2024, >25% QoQ growth; total revenue $63.5M includes $12.5M EU launch milestone.
Net loss improved to $10.7M from $39.2M in Q1 2023; cash position $209.8M as of March 31, 2024.
Raised FY 2024 BRIUMVI U.S. net revenue guidance to $270-290M (prior $220-260M) with Q2 target ~$65M.
Over 1,250 new BRIUMVI prescriptions in Q1; VA national formulary contract secured for anti-CD20 indications.
R&D spend $32.7M includes $8.8M license fee for azer-cel allogeneic CAR-T from Precision BioSciences.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TG THERAPEUTICS, INC. updated its the three months ended March 31, 2024 guidance (raised).

Period: the three months ended March 31, 2024
Guidance: raised
Result: reported results

Exact text from the filing

On May 1, 2024, TG Therapeutics, Inc. (the “Company”) issued a press release announcing results of operations for the three months ended March 31, 2024.

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

TG THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-24-014062

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.